ArticleJournal of translational medicine2025
Evaluation of immune-endothelial activation markers for the differentiation of severe dengue.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Mechanistic constraints in dengue severity: a systematic review with evidence stratification and agent-based evaluation of logical sufficiency.Frontiers in immunology · 2026Pooled it
- Dual Infection with dengue virus and infective endocarditis leading to brain abscess, multiorgan infarctions, and horner syndrome: a case report with literature review.BMC cardiovascular disorders · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundSevere dengue (SD) or dengue hemorrhagic fever is characterized by immune hyperactivation, endothelial dysfunction and vascular leakage. Early detection of the onset of SD, particularly during the febrile phase or before the onset of the critical phase is highly desirable. However, most dengue patients present late (≥ 5 days of illness) to the hospital, which coincides with the beginning of the critical phase. Biomarkers associated with these pathological processes may therefore serve as severity-associated markers. This study investigated the clinical utility of the immune-endothelial activation panel as a potential indicator for differentiating SD from dengue fever (DF).
methodsA multicenter cross-sectional study was conducted using sera of clinically- and laboratory-confirmed SD and DF patients, non-dengue febrile illness patients (NDFI) and healthy individuals. Serum levels of monocyte/macrophage activation markers CD163, CD14 and ferritin; endothelial activation and vascular permeability markers SDC-1 and VCAM-1; and cytokines CCL2, CCL3, CXCL9, CXCL10 and IL-10 were measured by ELISA or immunoplex assays. The ability to distinguish SD from DF was measured using Receiver Operating Characteristic (ROC) analysis.
resultsCD163, ferritin, SDC-1, VCAM-1 and CCL2 levels were significantly different between SD and DF, as well as between DF and NDFI. CD163, SDC-1 and VCAM-1 levels differed significantly between primary and secondary dengue. These indicators performed moderately as standalones in distinguishing SD from DF. However, a combination of SDC-1, CD163 and VCAM-1 improved diagnostic performance (AUC = 0.784, 95% Cl:0.725–0.835). Notably, combining AST, a hepatic injury marker with all four indicators (SDC-1, CD163, VCAM-1 and ferritin) significantly enhanced the diagnostic performance of this panel (AUC = 0.850, 95% Cl: 0.781–0.904).
conclusionA multi-marker panel consisting of immune-endothelial activation and hepatic injury can increase the accuracy of identifying SD during the critical phase of the illness. Given the absence of a specific test for the detection of impending SD, the strength of this multi-marker panel may support timely decision-making for high-risk patient management while safely discharging others to optimise the usage of hospital resources.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.